Clarity Financial LLC Sells 43,236 Shares of Johnson & Johnson (NYSE:JNJ)

Clarity Financial LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 91.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,106 shares of the company’s stock after selling 43,236 shares during the period. Clarity Financial LLC’s holdings in Johnson & Johnson were worth $702,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Biondo Investment Advisors LLC boosted its holdings in Johnson & Johnson by 1.8% during the third quarter. Biondo Investment Advisors LLC now owns 44,161 shares of the company’s stock worth $7,178,000 after purchasing an additional 785 shares during the last quarter. Marathon Capital Management lifted its stake in Johnson & Johnson by 4.6% in the third quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock valued at $4,404,000 after acquiring an additional 1,200 shares during the last quarter. Castle Rock Wealth Management LLC lifted its stake in Johnson & Johnson by 3.9% in the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock valued at $2,119,000 after acquiring an additional 479 shares during the last quarter. Blueshift Asset Management LLC lifted its stake in Johnson & Johnson by 671.9% in the third quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock valued at $4,904,000 after acquiring an additional 26,431 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its stake in Johnson & Johnson by 42.1% in the third quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock valued at $11,363,000 after acquiring an additional 20,404 shares during the last quarter. 67.84% of the stock is owned by institutional investors.

Shares of NYSE JNJ traded up $6.04 during mid-day trading on Tuesday, reaching $183.70. 681,286 shares of the company were exchanged, compared to its average volume of 7,890,662. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $184.20. The stock has a market capitalization of $483.00 billion, a P/E ratio of 22.75, a P/E/G ratio of 2.71 and a beta of 0.72. The company’s 50-day simple moving average is $172.50 and its 200-day simple moving average is $168.01. The company has a quick ratio of 1.12, a current ratio of 1.35 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping analysts’ consensus estimates of $2.61 by $0.06. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. The business had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. During the same period last year, the firm earned $2.59 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.48 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be issued a $1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.46%. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 54.29%.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.35% of the stock is owned by company insiders.

JNJ has been the subject of a number of recent analyst reports. Bank of America initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating for the company. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Raymond James raised their target price on shares of Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Thursday, April 14th. Finally, The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Buy” and a consensus target price of $184.57.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.